Last update 08 May 2025

Clindamycin/Ketoconazole

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms-
Target
50S subunit x CYP51A1
Action
inhibitors
Mechanism
50S subunit inhibitors(50S ribosomal subunit inhibitors), CYP51A1 inhibitors(Cytochrome P450 51 inhibitors)
Therapeutic Areas
Infectious DiseasesUrogenital Diseases
Active Indication-
Inactive Indication
Bacterial VaginosisCandidiasis, Vulvovaginal
Originator Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Active Organization-
Inactive Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
License Organization-
Drug Highest PhasePendingPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC26H28Cl2N4O4
InChIKeyXMAYWYJOQHXEEK-MKNUCDGGSA-N
CAS Registry65277-42-1
View All Structures (2)

Related

2
Clinical Trials associated with Clindamycin/Ketoconazole
NCT01293643
/ CompletedPhase 3
A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated
NCT00889356
/ Unknown statusPhase 3
Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis)
100 Clinical Results associated with Clindamycin/Ketoconazole
Login to view more data
100 Translational Medicine associated with Clindamycin/Ketoconazole
Login to view more data
100 Patents (Medical) associated with Clindamycin/Ketoconazole
Login to view more data
100 Deals associated with Clindamycin/Ketoconazole
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bacterial VaginosisPhase 3-
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
01 May 2010
Candidiasis, VulvovaginalPhase 3-
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
01 May 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free